2016 Clinical trials roundup: Steady Course or changing tides?

31 May 2016 by Doro Shin

Topics: Clinical Trials |

Provided by Trialtrove: gold standard clinical trials intelligence |

Here we’ll provide a high-level overview of trial activity, focused on the six major therapeutic areas (TAs) of autoimmune/inflammation, cardiovascular, CNS, infectious disease, metabolic/endocrinology, and oncology, with metrics by TA, trial phase, and disease.
We’ll then zoom in on the most active industry sponsors, including a closer look at how they may (or may not be) maximizing their assets.

Download the whitepaper for your clinical trial roundup from 2015, providing insight into how the course of pharma R&D has fared.

Highlights in this whitepaper include:

Round up of the 2015 debuts
Distribution of phases of unapproved drug trials per therapeutic area in 2015
Top 25 disease by trial count
Top locations for unapproved drug trials starting in 2015
Average number of countries disclosed per trial across most active industry sponsors